AstraZeneca and Aspen enter agreement for remaining rights to anaesthetics medicines

AstraZeneca announced that it has entered into an agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

• Source: Astrazeneca
• 477
• September 18, 2017